

**REMARKS**

Entry of the foregoing, reexamination and reconsideration of the instant application, pursuant to and consistent with 37 CFR § 1.111, are respectfully requested in light of the remarks which follow.

**STATEMENT OF THE SUBSTANCE OF THE INTERVIEW:**

Applicants and their undersigned representative thank Examiner Ibrahim for the courtesies extended during the telephone interview conducted on April 18, 2011, and before. During the interview, Claims 1, 2, and 14 were discussed. Also discussed during the interview were possible amendments to overcome the rejections under 35 U.S.C. § 102(b).

**SUMMARY OF AMENDMENTS**

By the foregoing amendments, Claim 1 has been amended to specify that it is an isolated nucleic acid consisting of the nucleotide sequence set forth in SEQ ID NO: 2 or SEQ ID NO: 22. This amendment is clerical in nature.

Further by the foregoing amendments, Claim 2 has been amended to make it dependent upon Claim 1. Support for this amendment may be found throughout the Specification, and at least at Page 4, Lines 6-11 and Page 5, Lines 3-12.

Further by the foregoing amendments, Claim 14 has been amended to reflect that it is a kit for the detection of CMV-resistant plant, which comprises the isolated nucleic acid of Claim 2. This amendment is clerical in nature.

**CONCLUSION**

In the event that there are any questions relating to this Amendment and Reply pursuant to 37 CFR § 1.111, or to the application in general, it would be appreciated if the Examiner would contact the undersigned attorney by telephone at (703) 836-6620 so that prosecution of the application may be expedited.

The Patent Office is hereby authorized to charge any necessary fees, or credit any overpayment, to Deposit Account No. 02-4800.

Respectfully submitted,

BUCHANAN INGERSOLL & ROONEY PC

By:

  
Charles F. Wieland III  
Registration No. 33,096

Date: April 21, 2011

**Customer No. 21839**  
703 836 6620